Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rovi enoxaparin versus Clexane pharmacodynamic equivalence crossover study in healthy volunteers
NL-OMON42485Active, not recruiting
- Sponsor
- Laboratorios Farmacéuticos ROVI
- Start
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of enoxaparin in deep vein thrombosis (DVT) (2 arms), sponsored by Laboratorios Farmacéuticos ROVI. Primary endpoint: Pharmacodynamic equivalence. Started Sep 2015; status: active, not recruiting.
02
Drugs
enoxaparin
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on NL-OMON42485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42485.